FDA moves to block brand name drugmakers from delaying generics

Published



The Food and Drug Administration is taking steps to prevent brand name drugmakers from organizing citizen petitions aimed at delaying approval of generic competition, which the agency says is unnecessarily bogging it down with meritless petitions.

FDA Commissioner Scott Gottlieb announced new regulatory guidance on Tuesday as part of a broader effort to crack down on practices that officials say brand name drugmakers use to stifle competition.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.